Loading...
SIGA logo

SIGA Technologies, Inc.NasdaqGM:SIGA Voorraadrapport

Marktkapitalisatie US$332.4m
Prijs aandeel
US$4.70
US$13.07
64.1% ondergewaardeerd intrinsieke korting
1Y-10.5%
7D3.8%
Portefeuillewaarde
​
Bekijk

SIGA Technologies, Inc.

NasdaqGM:SIGA Voorraadrapport

Marktkapitalisatie: US$332.4m

SIGA Technologies (SIGA) Aandelenoverzicht

SIGA Technologies, Inc., een farmaceutisch bedrijf in commerciële fase, richt zich op de markt voor gezondheidsbeveiliging in de Verenigde Staten. Meer informatie

Beloningen

Verhandeld tegen 64.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 91.31% per jaar groeien

Risicoanalyse

Winstmarges (24.6%) zijn lager dan vorig jaar (42.7%)


SIGA Community Fair Values

Create Narrative

See what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

SIGA Technologies, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor SIGA Technologies
Historische aandelenkoersen
Huidige aandelenkoersUS$4.70
52 Week HoogtepuntUS$9.62
52 Week LaagUS$4.29
Bèta0.85
1 maand verandering-9.62%
3 maanden verandering-27.80%
1 Jaar Verandering-10.48%
3 jaar verandering-19.38%
5 jaar verandering-31.09%
Verandering sinds IPO-10.48%

Recent nieuws en updates

Seeking Alpha • Dec 01

Siga Technologies: As Market Waits For MPOXX Purchases, I Remain On The Sidelines

Summary SIGA Technologies, Inc. remains a Hold as revenue uncertainty and lack of a new BARDA contract constrain upside. SIGA's business is highly profitable, with a strong cash position and no debt, but revenue is concentrated with the U.S. government. Recent Q3 results disappointed, with a sharp drop in share price and no new BARDA orders, highlighting dependency risk. International expansion faces regulatory reassessment and rising manufacturing costs, while future SIGA growth hinges on contract renewals and pipeline progress. Read the full article on Seeking Alpha
Analyse-artikel • Nov 14

Take Care Before Jumping Onto SIGA Technologies, Inc. (NASDAQ:SIGA) Even Though It's 26% Cheaper

SIGA Technologies, Inc. ( NASDAQ:SIGA ) shareholders that were waiting for something to happen have been dealt a blow...

Recent updates

Seeking Alpha • Dec 01

Siga Technologies: As Market Waits For MPOXX Purchases, I Remain On The Sidelines

Summary SIGA Technologies, Inc. remains a Hold as revenue uncertainty and lack of a new BARDA contract constrain upside. SIGA's business is highly profitable, with a strong cash position and no debt, but revenue is concentrated with the U.S. government. Recent Q3 results disappointed, with a sharp drop in share price and no new BARDA orders, highlighting dependency risk. International expansion faces regulatory reassessment and rising manufacturing costs, while future SIGA growth hinges on contract renewals and pipeline progress. Read the full article on Seeking Alpha
Analyse-artikel • Nov 14

Take Care Before Jumping Onto SIGA Technologies, Inc. (NASDAQ:SIGA) Even Though It's 26% Cheaper

SIGA Technologies, Inc. ( NASDAQ:SIGA ) shareholders that were waiting for something to happen have been dealt a blow...
Analyse-artikel • Aug 08

SIGA Technologies, Inc.'s (NASDAQ:SIGA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

NasdaqGM:SIGA 1 Year Share Price vs Fair Value Explore SIGA Technologies's Fair Values from the Community and select...
Seeking Alpha • Apr 07

SIGA Technologies: Asymmetric Upside, If 2025 Goes Right

Summary SIGA Technologies' strong cash position and high FCF margins provide a valuation floor, but growth is limited without new catalysts, supporting a "speculative Buy" rating. Key 2025 catalysts include potential PEP approval and a new BARDA contract, which could significantly boost SIGA's valuation. SIGA's reliance on unpredictable orthopoxvirus outbreaks and government funding poses risks, making it suitable for a barbell portfolio with speculative investment. Investors should be cautious of budget cuts, underwhelming clinical trials, and the uncertain future of government funding and orthopoxvirus outbreaks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 02

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

Summary SIGA Technologies, Inc.'s reliance on TPOXX, coupled with mixed clinical trial results, and the need to renew the contract with the U.S. in 2025, shed doubts about Siga’s long-term outlook. Emergent BioSolutions Inc.'s diversified product portfolio and turnaround strategy under new CEO Joseph Papa provides an optimistic long-term outlook. Siga's financial stability is threatened by potential policy changes driven by the new U.S. government and TPOXX's uncertain efficacy against mpox. Emergent's improved operations, Narcan's growth, and favorable valuation metrics position it for high returns despite past performance challenges. Read the full article on Seeking Alpha
Seeking Alpha • Nov 21

SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket

Summary SIGA Technologies' stock has declined 37% since my "speculative buy" recommendation in August, driven by a muted response to the mpox outbreak. The initial recommendation was based on the WHO's mpox emergency declaration and potential increased demand for SIGA's lead asset, tecovirimat. The mpox outbreak has waned, and global authorities' response has been less aggressive, leading to lower-than-expected demand for tecovirimat. SIGA's research expansion into monoclonal antibodies (mAbs) for orthopoxviruses makes perfect sense, but it doesn't provide much diversification. SIGA remains a speculative buy despite the short-term volatility. Investors, however, should allocate no more than what they can afford to lose. Read the full article on Seeking Alpha
Analyse-artikel • Nov 15

Investors Shouldn't Be Too Comfortable With SIGA Technologies' (NASDAQ:SIGA) Earnings

SIGA Technologies, Inc.'s ( NASDAQ:SIGA ) robust earnings report didn't manage to move the market for its stock. We did...
Analyse-artikel • Sep 14

SIGA Technologies, Inc. (NASDAQ:SIGA) Not Doing Enough For Some Investors As Its Shares Slump 34%

The SIGA Technologies, Inc. ( NASDAQ:SIGA ) share price has softened a substantial 34% over the previous 30 days...
Seeking Alpha • Aug 15

SIGA Technologies: Shares Tanking On Mpox Study Miss, Turbulence May Be Temporary

Summary SIGA Technologies, Inc. stock is reeling today after the company reported its lead and only drug tecovirimat missed its primary endpoint in a study in patients with Mpox. The timing is unfortunate, given the day before, the WHO announced a Mpox global health emergency — with cases reported in DRC, Central & East Africa, and Sweden. Despite the study miss, the company's core business of supplying oral and IV TPOXX to governments remains the key determinant of its share price. Nevertheless, the turbulent share price has created something of a storm for the company and its shareholders, and there may be more price volatility to come. Read the full article on Seeking Alpha
Analyse-artikel • Jul 14

SIGA Technologies, Inc. (NASDAQ:SIGA) Held Back By Insufficient Growth Even After Shares Climb 31%

SIGA Technologies, Inc. ( NASDAQ:SIGA ) shareholders are no doubt pleased to see that the share price has bounced 31...
Seeking Alpha • Jun 13

SIGA Technologies: BARDA Contract Renewal Required To Sustain Recent Momentum (Rating Downgrade)

Summary SIGA Technologies is a pharmaceutical company selling TPOXX to the US and international governments, with a profitable business model. Revenue primarily comes from contracts with the US government, with potential risks due to heavy reliance on BARDA contract renewal. This contract may be renegotiated with a few issues, and approvals in PEP and pediatric settings, although seemingly it is not yet confirmed. SIGA stock can spike when infectious disease scares occur - i.e. in 2022 during a mpox outbreak, but generally speaking, the company is fairly valued, with a small market restricting growth prospects. Read the full article on Seeking Alpha
Analyse-artikel • Mar 31

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company

The SIGA Technologies, Inc. ( NASDAQ:SIGA ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Mar 25

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Summary SIGA stock is setting new 52-week highs after a strong earnings report. The post-earnings rally is also supported by a special cash dividend of $0.60, going ex-dividend on 25 March. Perhaps the most important question on investors’ minds would be if it is too late to buy the stock. Despite the rally, the stock still trades at a discount to its 5-year averages on several valuation metrics. Assigning a “Buy” rating and price target of at least ~$10 for the stock given Siga’s strong positioning to benefit from the heightened focus and global spending on health security. Read the full article on Seeking Alpha
Analyse-artikel • Mar 19

Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality

When companies post strong earnings, the stock generally performs well, just like SIGA Technologies, Inc.'s...
Analyse-artikel • Feb 15

The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)

You may think that with a price-to-sales (or "P/S") ratio of 10.2x SIGA Technologies, Inc. ( NASDAQ:SIGA ) is a stock...
Analyse-artikel • Jan 13

Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Seeking Alpha • Sep 29

SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX

SIGA Technologies (NASDAQ:SIGA) notifies that the U.S. Department of Defense awarded a new contract to SIGA for the procurement of up to $10.7M of oral TPOXX, of which $5.1M of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD. The contract follows an award made earlier this year for the procurement of $7.4M of oral TPOXX, under which all product is expected to be delivered in 2022.    The project work is supported by a separate development contract worth ~$26M. Shares are up 3.12% premarket.
Seeking Alpha • Sep 09

Siga monkeypox therapy undergoes NIH-led late-stage trial

On Friday, the National Institutes of Health (NIH) announced the start of a late-stage clinical trial to test Siga Technologies’ (NASDAQ:SIGA) Tpoxx antiviral pill on monkeypox patients. Tpoxx, approved in the U.S. for related smallpox infection, is also used to treat monkeypox on a case-by-case basis under the FDA's Expanded Access program. The NIH-led trial is expected to enroll 500 patients, both adults and children, who will be randomized to receive Tpoxx, also known as Tecovirimat, and the placebo. The study is designed to measure if Tpoxx recipients heal faster than those who receive the placebo and obtain critical data on optimal dosing and safety for children and pregnant women. Recently, a team of British scientists, who conducted one of the major clinical trials to find COVID-19 therapies, started a similar trial for Tpoxx in the U.K.
Seeking Alpha • Aug 23

Scientists behind key COVID study run monkeypox trial for SIGA therapy

A team of British scientists, who conducted one of the major trials to find COVID-19 therapies, announced a new clinical study on Tuesday to evaluate whether the antiviral tecovirimat developed by SIGA Technologies (NASDAQ:SIGA) is effective against monkeypox. The scientists from Oxford University rose to fame in 2020 after initiating their so-called RECOVERY trial, which initially tested four treatments against COVID-19. Tecovirimat, also known as TPOXX, is currently available in the U.S. as a treatment for smallpox on a case-by-case basis under the FDA's Expanded Access program. The monkeypox trial named PLATINUM is funded by a ~$4.4M grant from the U.K. government. The randomized trial will enroll at least 500 participants who will receive a 14-day course of 600mg tecovirimat twice daily or a matched placebo. Previously, updating on its plans to launch global studies for TPOXX in monkeypox, SIGA (SIGA) said that the first trial sites in the U.K. would be activated this week.
Seeking Alpha • Aug 17

SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg

SIGA Technologies (NASDAQ:SIGA), the maker of smallpox therapy TPOXX, plans to start clinical trials for its lead product, activating trial sites in the U.K. for the first-time next week to evaluate the treatment against the related monkeypox virus Bloomberg reported Wednesday. During an interview, SIGA's (SIGA) Chief Scientific Officer Dennis E. Hruby said that the U.K. studies would represent the first of a dozen clinical trial sites to be activated globally in the latest monkeypox outbreak. According to Our World in Data, monkeypox has led to over 38,000 cases in the recent outbreak. The U.S. has reported more than 12,600 monkeypox cases as of Aug. 16, the data from the Centers for Disease Control and Prevention (CDC) indicates. TPOXX is currently available in the U.S. as a treatment for smallpox on a case-by-case basis under the FDA's Expanded Access program.
Analyse-artikel • Aug 12

Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)

Today we will run through one way of estimating the intrinsic value of SIGA Technologies, Inc. ( NASDAQ:SIGA ) by...
Seeking Alpha • Aug 09

SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise

SIGA Technologies (NASDAQ:SIGA) announced Tuesday that the company will deliver approximately $26M worth of treatment courses of its lead product TPOXX in 2023 after the U.S. government decided to exercise a procurement option. TPOXX, indicated in the U.S. for smallpox, is currently used to treat monkeypox under the FDA’s Animal Rule. The exercise of procurement options under its 75A50118C00019 (19C) contract with the U.S. Department of Health and Human Services (HHS) by the Biomedical Advanced Research and Development Authority (BARDA) requires SIGA (SIGA) to deliver the IV formulation of TPOXX. “The exercised options are among many procurement options under the 19C contract that remain to be exercised,” Chief Executive Phil Gomez remarked. The unexercised options under the 19C BARDA Contract amount to potential payments up to approximately $311.1M in total, SIGA (SIGA) disclosed in its latest 10-Q filing.
Seeking Alpha • Aug 01

SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play

After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpox and/or monkeypox, further de-risking the equity story. An FDA statement shows the agency wants to increase the usage of TPOXX through expanded access or compassionate use program. We upgrade SIGA's rating to a strong buy. SIGA Technologies' (SIGA) sell-off that happened on July 29th was unwarranted, and it represents an excellent buying opportunity for investors: SIGA data by YCharts Right after the FDA update on July 29th, the stock sold off 30%+ at one point without any fundamental reason. We speculate it is likely due to: 1) a high degree of short-sellers going stop-loss hunting; and 2) some investors may have misunderstood some of the FDA's statements around human data. Safety and efficacy of TPOXX to treat monkeypox in humans has not been established. Conducting randomized, controlled trials to assess TPOXX's safety and efficacy in humans with monkeypox infections is essential. We don't currently know if TPOXX will be beneficial, harmful, or have no effect in treating patients with monkeypox, since drugs that are effective in animal studies are not always effective in humans. Source: FDA (Click) The key point to remember is that even if the drug does not have human efficacy data, TPOXX is approved for smallpox by: 1) the FDA in 2018 (Click); 2) Canada in 2021 December (Click) for smallpox; and 3) recently received approval in the UK (Click) for monkeypox on July 8, 2022. We highlight that the human trial is not required, as the approval pathway follows animal rule regulation because smallpox is eradicated, and considering the nature of the disease, it is "not ethical nor feasible to test" the drug in humans. TPOXX clearly showed efficacy in animals (rabbits and non-human primates) that were infected with monkeypox. We continue to build a high degree of conviction on TPOXX's usage for treating monkeypox. FDA approved TPOXX in 2018 for treatment of smallpox based on efficacy data obtained from animal studies, specifically non-human primates infected with monkeypox virus and rabbits infected with rabbitpox virus. Such studies were relevant since the viruses that cause smallpox, monkeypox, and rabbitpox are in the same family of viruses called "orthopoxviruses." Safety data was obtained in healthy human volunteers without a smallpox or monkeypox infection. Source: FDA (Click) FDA's update de-risks the potential concerns around patient accessibility: ... TPOXX (tecovirimat), an antiviral medication, is being made available through the CDC under an FDA authority called Expanded Access or "compassionate use." The FDA continues to work with the CDC to streamline their Expanded Access Program for monkeypox to facilitate access. There are currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox, or the safety and pharmacokinetic profile (which helps us understand what the human body does to a drug). Although expanded access program is available, conducting randomized, controlled trials to assess TPOXX's safety and efficacy in humans with monkeypox infections is essential. The FDA has more information on TPOXX's approval for smallpox under the "Animal Rule" regulations on its monkeypox webpage. - July 29 FDA (Click) The key limitation to our initial thesis was that, regardless of the stockpiling, actual patient access to TPOXX could be challenging due to complexities in regards to the process of patients actually getting TPOXX. For example, patients may need to find physicians who are principal investigators and file an IND that needs to be approved by the IRB, which can take a long time, and patients need to actually enroll in a clinical trial in order to receive the treatment. The CDC holds an Expanded Access Investigational New Drug protocol (EA-IND) that allows for the use of TPOXX for treatment of orthopoxvirus infections other than variola (which is the virus that causes smallpox), including monkeypox, in adults and children of all ages. The EA-IND provides an umbrella regulatory coverage, so clinicians and facilities do not need to request and obtain their own INDs. The FDA worked closely with the CDC to streamline the protocol to reduce data collection and reporting requirements. The revised protocol is now available for use. Source: FDA (Click) However, the recent FDA statement clearly shows that FDA will allow the drug to be used under the Expanded Access Investigational New Drug protocol (EA-IND) where physicians "do not need to request and obtain their own INDs."
Seeking Alpha • Jul 25

SIGA Technologies: Buy Monkeypox

WHO’s declaration of a monkeypox global health emergency points to an increasing need for treatment, which is why SIGA is about to print large amounts of cash. The downside is low: SIGA is a debt-free company sitting on $150M in cash. The current DCF analysis determines SIGA to be undervalued by 68%. I briefly mentioned being long SIGA Technologies (SIGA) in the recent earnings roundtable and received quite a few questions in response. I figure with WHO declaring monkeypox a global health emergency, now is a good time to give my thoughts on SIGA for Seeking Alpha readers. Monkeypox Is Not 2019-nCoV Let me start by tooting my own horn while also warning some readers that this is not a repeat of my past success. I was the first person on Seeking Alpha to recommend hedging against a market crash due to the outbreak of Covid-19 (then called 2019-nCoV), so it might seem as though I have a knack for this sort of thing. Whether I do or not, those asking me whether monkeypox will be another 2020-type event for the market should know that I don't think monkeypox represents the same type of downside threat and thus we aren't looking at shorting the entire market. Rather, I believe that monkeypox will have the same type of effect on vaccine stocks that Covid-19 did, without the strong downside pull on the entire market that Covid did. Thus, we are looking at long positions on companies comfortably positioned to profit from monkeypox instead of short positions on stocks that are likely to fall hard (as we did in 2019 with cruise stocks). After much research, I recommended my subscribers take a position in SIGA. I'll say here what I told my newsletter subscribers: This position is a lottery ticket but with a risk/reward that greatly favors the buyer. So far, the play has paid off, but the upward movement thus far has been due to hype more so than actual fundamentals - but that might just be enough to make quadruple-digit ROI regardless of the long-term trajectory of monkeypox. SIGA's TPOXX and Monkeypox Clearly, I could not have known that WHO would call monkeypox a global emergency when I made the recommendation, but I believe both WHO and I were working with the same data. I worked on mathematical virus models for my senior project for my BS in mathematics in the University of Washington, and I had applied that knowledge to both the initial data of 2019-nCoV and monkeypox before putting my money down. I think, if anything, WHO's declaration only adds strength to my hypothesis that monkeypox will spread exponentially, creating urgent need for treatment, which is where SIGA comes in. SIGA distributes TPOXX, an anti-viral treatment for human smallpox caused by variola virus. Variola virus is a family of virus, similar to coronavirus being a family of virus that causes Covid, SARS, and the common cold. Monkeypox belongs to the variola virus family and is thus a target for TPOXX. Although it has not been used in human studies, TPOXX has shown efficacy in cell culture studies, reducing virus-induced cytopathic effect by 50% for monkeypox. It has also been used in primate studies, greatly increasing the survival rate of cynomolgus macaques injected with lethal amounts of monkeypox. The initial data at this point shows TPOXX to be an extremely promising treatment for this "global health emergency," and SIGA stands to profit greatly. The Upside The main downside up to this point has been red tape. Doctors have been consistently reporting difficulty in dealing with the bureaucracy in prescribing TPOXX, despite doctors recommending and patients asking for this treatment. With WHO declaring an emergency, we can reasonably believe that - as with the Covid-19 vaccines - the red tape will be cut away for the sake of saving lives. Naturally, the result is more TPOXX sales, leading to better financial numbers for SIGA, thereby increasing stock price. So the idea here is a huge upside, based on the spread of monkeypox. But one reason I recommended this stock is its financial health. This is not an unprofitable, unproven meme biotech hype stock. The downside is quite low, judging from the fundamentals. For example, this is a debt-free company sitting on $150M in cash. Simply Wall St With increasing TPOXX sales, we should expect a significant jump in cash flow, which naturally raises the probability of dividends as well as the valuation as per a discounted cash flow analysis. And on that note, even the current DCF analysis determines SIGA to be undervalued: Damon Verial Damon Verial Damon Verial Damon Verial Damon Verial From a price-to-earnings perspective, too, SIGA is underpriced. The average pharmaceutical stock has a PE of 22x, while SIGA trades at a little over 12x: Simply Wall St
Seeking Alpha • Jul 08

Siga Technologies receives approval from UK for tecovirimat

United Kingdom has approved SIGA Technologies's (NASDAQ:SIGA) oral tecovirimat for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. Similar formulation of tecovirimat was approved by the U.S. Food and Drug Administration in 2018 and by Health Canada in late 2021 under the brand name TPOXX for the treatment of smallpox. In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection. Vaccine developers for monkeypox: Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY), Emergent BioSolutions (EBS), Chimerix (CMRX). Developers of monkeypox therapeutics: GeoVax Labs (GOVX), SIGA Technologies (SIGA) and Tonix Pharmaceuticals (TNXP). Developers of diagnostics for monkeypox: Co-Diagnostics (CODX), Roche (OTCQX:RHHBY) (OTCQX:RHHBF), Abbott Laboratories (ABT). Read: In a previous meeting last month, WHO’s Emergency Committee declined to issue the PHEIC designation for the current monkeypox outbreak. Shares of SIGA are up 5.1% premarket.
Seeking Alpha • May 27

SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak

SIGA Technologies' share price has been soaring as a result of approval for its IV smallpox therapy. The company's TPOXX formulation was also recently approved in Europe for indications including smallpox and monkeypox. The monkeypox outbreak is being monitored closely in case there is another pandemic in prospect. It's unlikely, but Siga is one of a handful of companies with a potential therapeutic. SIGA's core business justifies its rising share price in my opinion, but the monkeypox outbreak may drive further upside. I make the company a solid buy opportunity.
Seeking Alpha • Dec 12

SIGA Technologies: There's An Assured Market For A Smallpox Vaccine

SIGA develops smallpox vaccines. Smallpox has been eradicated. However, the US and other governments buy these vaccines for hundreds of millions of dollars.

Rendement voor aandeelhouders

SIGAUS PharmaceuticalsUS Markt
7D3.8%6.2%3.2%
1Y-10.5%33.4%31.0%

Rendement versus industrie: SIGA presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 33.4 % opleverde.

Rendement versus markt: SIGA presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31 % opleverde.

Prijsvolatiliteit

Is SIGA's price volatile compared to industry and market?
SIGA volatility
SIGA Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stabiele aandelenkoers: SIGA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van SIGA is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
199549Diem Nguyenwww.siga.com

SIGA Technologies, Inc., een farmaceutisch bedrijf in commerciële fase, richt zich op de markt voor gezondheidsbeveiliging in de Verenigde Staten. Het belangrijkste product van het bedrijf is TPOXX, een antiviraal geneesmiddel voor de behandeling van de menselijke pokkenziekte veroorzaakt door het variolavirus. SIGA Technologies, Inc. werd opgericht in 1995 en het hoofdkantoor is gevestigd in New York, New York.

SIGA Technologies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van SIGA Technologies zich tot de beurswaarde?
SIGA fundamentele statistieken
MarktkapitalisatieUS$332.43m
Inkomsten(TTM)US$23.28m
Inkomsten(TTM)US$94.57m
14.5x
Koers/Winstverhouding
3.6x
P/S-verhouding

Is SIGA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SIGA resultatenrekening (TTM)
InkomstenUS$94.57m
Kosten van inkomstenUS$49.66m
BrutowinstUS$44.91m
Overige uitgavenUS$21.64m
InkomstenUS$23.28m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

May 07, 2026

Winst per aandeel (EPS)0.32
Brutomarge47.49%
Nettowinstmarge24.61%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde SIGA op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

12.8%
Huidig dividendrendement
n/a
Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/06 13:53
Aandelenkoers aan het einde van de dag2026/05/06 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

SIGA Technologies, Inc. wordt gevolgd door 4 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Jyoti PrakashEdison Investment Research
Nancy HullLadenburg Thalmann & Company
Adnan ButtRBC Capital Markets